FDA Probes Intuitive Surgical on Complication Rates
The FDA surveys doctors on complications experienced using Intuitive Surgical's da Vinci surgical robot, sending shares down on Wall Street.
New of the probe, first reported by Bloomberg, sent ISRG shares down 11.1% to $509.89 apiece on Wall Street yesterday. The stock recovered some of that today, hitting $547.62 in pre-market trading and reaching $552.47 each as of about 11 this morning.
The FDA asked surgeons at "key hospitals" to detail any complications they've seen with the da Vinci robot, according to a copy of the survey obtained by the news service. The survey also asked about procedures the device might be good for and those it might not be ideal for and about the training they received on using the device.